- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01697891
A Pilot Study of ALTENS in Improving Dysphagia Induced by IMRT for Head and Neck Cancers
Effectiveness of Acupuncture-like Transcutaneous Nerve Stimulation (ALTENS) in Improving Dysphagia and Associated Symptoms of Chemotherapy and/or Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Cancers: A Pilot Study
Study hypothesis: ALTENS techniques, administered within the first 3 months after radiation completion, can improve radiation-induced dysphagia and associated symptoms in head and neck cancer patients. This beneficial effect is mediated by the reduction of chronic inflammatory response of swallowing musculature to radiation, consequently a reduction in muscle fibrosis.
Primary study objective: To evaluate the effectiveness of ALTENS in relieving radiation-induced dysphagia. Eating Assessment Tool (EAT-10) scores will be used for this primary study endpoint.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V5C2
- Juravinski Cancer Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:This study will recruit patients with head and neck cancers treated with radiation+/- chemotherapy and who meet the following criteria (EAT-10 assessment will be used for screening):
Inclusion Criteria
- present with dysphagia symptoms
- with no evidence of residue cancer
- are within 3 months (but past 1 month) after treatment completion
- show positive dysphagia (EAT-10 score of > 3) and/ or aspiration on barium swallow study
- are over 18 years old
- are able to read and write fluent English
- can give informed consent
Exclusion Criteria:
- have unstable heart disease
- have infectious disease transmissible by blood or body fluid, including hepatitis and HIV
- have skin disease at site of study acupuncture points that prevents the application of electrodes
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ALTENS
Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
|
ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment.
Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline
Tidsramme: 3 months after treatment completion
|
EAT-10 is a self-administered questionnaire for subjective assessment of dysphagia.
It consists of 10 items and each item is scored using a 5-point Likert scale.
The higher the point, the more severe the problem being scored.
Normative data suggested that a total score of 3 or higher is abnormal.
|
3 months after treatment completion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in M. D. Anderson dysphagia inventory from baseline
Tidsramme: 3 months after treatment completion
|
M. D. Anderson dysphagia inventory (MDADI) is a self-administered questionnaire designed specifically to assess the quality of life for head and neck cancer patients who suffer from dysphagia.
It incorporated three domains: emotional, functional and physical, and one global question.
There are a total of 20 items.Each item is scored on a scale of 1 to 5 with 1 being strongly agree and 5 strongly disagree except for two items, one on the emotional subscale and the other on the functional subscale.
The global question is scored and interpreted separately.
The scores of all the items in each domain are summed and a mean score is calculated.
The final score for each subscale is calculated by multiplying the calculated mean score by 20 with a final range from 0 to 100.
The final score of the global question is also calculated in the same way.
The higher the final score represents better functioning and quality of life.
|
3 months after treatment completion
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Raimond Wong, MD, McMaster University
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MU12-530
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Codetron ALTENS
-
Masonic Cancer Center, University of MinnesotaAfsluttetFIGO Stadium III og IV Ovariekræft | FIGO Stage III og IV Æggelederkræft | FIGO Stage III Primær Peritoneal CancerForenede Stater
-
Centre of Postgraduate Medical EducationRekruttering
-
John SampsonAfsluttet
-
Masonic Cancer Center, University of MinnesotaUniversity of MinnesotaTrukket tilbageSekundær akut myeloid leukæmi | Myelodysplastisk syndrom | Behandlingsrelateret akut myeloid leukæmi | Højrisiko Akut Myeloid LeukæmiForenede Stater
-
Synvista Therapeutics, IncAfsluttetLungeødem | Dyspnø | Hjertesvigt, kongestivForenede Stater
-
Altimmune, Inc.Afsluttet
-
Synvista Therapeutics, IncNational Institutes of Health (NIH); National Heart and Lung InstituteAfsluttetKardiovaskulær sygdomForenede Stater
-
University of UtahImmunityBio, Inc.Trukket tilbageB-celle non-hodgkin lymfomForenede Stater
-
Al-Yasmeen Fertility and Gynecology CenterUkendt
-
National Cancer Institute (NCI)Ikke rekrutterer endnuNeoplasmer | Neoplasmer efter histologisk type | Adenocarcinom | Karcinom | Neoplasmer, kirtel og epitel | ProstatakræftForenede Stater